Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Cost of Revenue (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Cost of Revenue data on record, last reported at $1.4 million in Q3 2025.

  • For Q3 2025, Cost of Revenue fell 12.09% year-over-year to $1.4 million; the TTM value through Sep 2025 reached $6.8 million, down 24.4%, while the annual FY2024 figure was $7.8 million, 63.78% up from the prior year.
  • Cost of Revenue reached $1.4 million in Q3 2025 per TNXP's latest filing, down from $3.3 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $3.4 million in Q2 2024 and bottomed at $943000.0 in Q1 2025.
  • Average Cost of Revenue over 3 years is $2.0 million, with a median of $1.6 million recorded in 2024.
  • Peak YoY movement for Cost of Revenue: plummeted 50.02% in 2024, then fell 2.82% in 2025.
  • A 3-year view of Cost of Revenue shows it stood at $2.4 million in 2023, then tumbled by 50.02% to $1.2 million in 2024, then rose by 15.55% to $1.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $1.4 million in Q3 2025, $3.3 million in Q2 2025, and $943000.0 in Q1 2025.